Phase II trial of combination weekly bortezomib (Velcade) and docetaxel (Taxotere) in patients with recurrent and/ or metastatic head and neck squamous cell carcinoma (HNSCC).

Trial Profile

Phase II trial of combination weekly bortezomib (Velcade) and docetaxel (Taxotere) in patients with recurrent and/ or metastatic head and neck squamous cell carcinoma (HNSCC).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2011

At a glance

  • Drugs Bortezomib (Primary) ; Docetaxel
  • Indications Head and neck cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 01 Apr 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 25 Nov 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 16 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top